China-Australia Free Trade Agreement – The Healthcare Opportunity

China-Australia Free Trade Agreement – The Healthcare Opportunity

China is Australia’s largest trading partner – worth $8.8 billion in 2014-2015. China and Australia are also growing partners in science and research and this is an important area for growth in bilateral relations. China is and has been Australia’s key focus for science and research collaboration efforts; generating advances in medical research, biodiversity, net […]

Read More

December 26th, 2016

Preventing cardiovascular disease through a simple text message

The World Health Organization states that cardiovascular disease (CVD) has been the number one global cause of death; with an estimation of 17.5 million people dying from CVD in 20121, representing 31% of all global deaths. CVD has been and is currently the major cause of death in Australia2 accounting for over 43,600 deaths in […]

Read More

December 23rd, 2016

mHealth integration in China

Over the past years, the number of mobile phone subscribers in China has been increasing at an exponential rate. By the end of 2015, there was approximately 202.47 million cell phones produced in China1 along with 1,033.6 million mobile users registered in China, with the number of users expected to grow to 1,086.8 by 2019. […]

Read More

November 25th, 2016

Outsourcing criteria within the Asia-Pacific

George Clinical (GC) conducted a brief survey on sponsors who are currently not a customer of GC.  30 companies were surveyed by GC’s Business Development Managers across six countries which included the United States, China, Australia, Korea, United Kingdom and Israel. The primary objective of the survey was to determine the services and countries that were important […]

Read More

September 3rd, 2015

Sulfagenix Inc. leverages the R&D Tax Incentive in Australia

Sulfagenix, Inc., a United States based biotech, was able to tap into Australia’s world class research and development (R&D) facilities and expertise

Read More

April 24th, 2015

Does air pollution cause COPD?

Chronic obstructive pulmonary disorder (COPD) is now the third most frequent cause of death in the world; however the cause of this disease for a substantial proportion of patients remains unknown.

Read More

February 25th, 2015

Update to Australia’s R&D tax incentive

The R&D Tax Incentive is a targeted, generous and easy to access entitlement program that helps businesses offset some of the costs of doing R&D. The Program aims to help more businesses do R&D and innovate. It is a broad-based entitlement program. This means that it is open to firms of all sizes in all […]

Read More

June 2nd, 2014

Australia

George Clinical is an Australian owned organization headquartered in Sydney, Australia. In Sydney, we are co-located with our parent organization, The George Institute, a world leading medical research institute. From this location, we oversee our operations throughout Asia-Pacific. Australia is an attractive place to conduct clinical research with an efficient regulatory process, highly experienced research […]

Read More

May 26th, 2014

R&D tax incentives for George Clinical services

There’s no better time to be working with us. The Australian Tax Office will provide a tax incentive to encourage R&D activities in Australia, jointly administered by AusIndustry. Companies with < $20m per annum turnover can be eligible for 45% refundable tax offset; and other companies can be eligible for a non-refundable 40% tax offset. […]

Read More

August 28th, 2013

required
required
required
required
I wish to subscribe to George Clinical communications.
required

Add George Clinical to your network